InvestorsHub Logo
Followers 35
Posts 6905
Boards Moderated 1
Alias Born 04/04/2020

Re: Bouf post# 417663

Saturday, 11/04/2023 6:30:14 PM

Saturday, November 04, 2023 6:30:14 PM

Post# of 427173
Bouf, Three years after the entry of the first generic and we still hold the majority of the market. Why is that? This is not a drug that can be produced In mass cheaply. The standard generic playbook doesn't work on this. Amarin has been able to compete. The market will grow over time. Generic companies will most likely have their piece and we ours. What the potential size of that market will be is key for determining the success of our investment.
Sleven,
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News